AcelRx raises ~$10M via private placement of common stock and warrants

TALPHERA, INC.

Gross proceeds ~$10M from sale of 5.34M shares, pre-funded warrants for 2.01M shares, and Series A/B warrants for 7.35M shares each at $1.11 exercise price; combined price $1.36.
Closing expected July 20, 2023; placement agent H.C. Wainwright receives 5.25% fee, expense reimbursement up to $100k, and $200k if warrant exercise proceeds exceed $9.5M.
Registration rights agreement requires filing resale registration statement within 15 days, effectiveness within 90 days.
Series A/B warrants exercisable immediately, 5-year term; Series A term shortens to 45 days upon FDA EUA for Niyad; Series B term shortens upon successful registrational trial for Niyad.

item 1.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TALPHERA, INC. entered into Registration Rights Agreement with the Purchasers (effective 2023-07-17).

Action: entry
Counterparty: the Purchasers
Effective: 2023-07-17

Exact text from the filing

We entered into a registration rights agreement, dated July 17, 2023, with the Purchasers pursuant to which we have agreed to file a registration statement

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TALPHERA, INC. entered into Purchase Agreement with several institutional investors valued at approximately $10.0 million (effective 2023-07-17).

Action: entry
Agreement: equity purchase
Counterparty: several institutional investors
Value: approximately $10.0 million
Effective: 2023-07-17

Exact text from the filing

On July 17, 2023, AcelRx Pharmaceuticals, Inc., or AcelRx, entered into a securities purchase agreement, or the Purchase Agreement, with several institutional investors, or the Purchasers, relating to the issuance and sale to the Purchasers in a private placement of

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-020383

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.